These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

650 related items for PubMed ID: 9280685

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Levodopa in the early treatment of Parkinson's disease.
    Murata M.
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [Abstract] [Full Text] [Related]

  • 6. Effective strategies in the management of Parkinson's disease.
    Wills AJ.
    Hosp Med; 1998 Apr; 59(4):287-90. PubMed ID: 9722367
    [Abstract] [Full Text] [Related]

  • 7. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Opioids and motor complications in Parkinson's disease.
    Samadi P, Bédard PJ, Rouillard C.
    Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
    [Abstract] [Full Text] [Related]

  • 10. Recognition and treatment of response fluctuations in Parkinson's disease: review article.
    Verhagen Metman L.
    Amino Acids; 2002 Oct; 23(1-3):141-5. PubMed ID: 12373528
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Current controversies: levodopa in the treatment of Parkinson's disease.
    Sharma JC, Vassallo M, Ross IN.
    Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
    Olanow CW, Jankovic J.
    Mov Disord; 2005 May; 20 Suppl 11():S3-10. PubMed ID: 15822111
    [Abstract] [Full Text] [Related]

  • 16. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.
    Vidailhet M, Bonnet AM, Marconi R, Durif F, Agid Y.
    Mov Disord; 1999 May; 14 Suppl 1():13-8. PubMed ID: 10493399
    [No Abstract] [Full Text] [Related]

  • 17. [Early treatment of Parkinson's disease with levodopa].
    Odekerken VJ, Post B, Verschuur CV, de Bie RM.
    Ned Tijdschr Geneeskd; 2009 May; 153():A286. PubMed ID: 19785822
    [Abstract] [Full Text] [Related]

  • 18. [Physiopathology of the dyskinesias induced by L-dopa].
    Grandas F, López-Ariztegui N.
    Rev Neurol; 1997 Aug; 25 Suppl 2():S151-6. PubMed ID: 9280682
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.